List of contraindications for somituximab (Mirvetuximab)

Mirvetuximab (Mirvetuximab) is an effective treatment option for many ovarian cancer patients, but it may not work for all patients. Based on the drug's clinical use guidelines and approval literature, the following is a list of people for whom this drug is contraindicated:

1. Patients with known allergy to this drug or its ingredients: If patients have an allergic reaction to somituximab or any excipients of the drug (such as ingredients in the drug), they should avoid using this drug.

2. Pregnant women: Although there is currently insufficient clinical data for use during pregnancy, considering the potential risks that the drug may cause to the fetus, pregnant women should avoid using this drug unless it is fully evaluated under the guidance of a doctor and the benefits are deemed to outweigh the risks. The use of such drugs during pregnancy may increase the risk of fetal development defects and premature birth.

3. Breastfeeding women: Since the drug may be secreted through breast milk, breastfeeding women should avoid using this drug. Breastfeeding mothers should stop breastfeeding when using somituximab to avoid potential risks to the health of their infants.

4. Patients with severe liver function impairment: The metabolism of somituximab is mainly carried out by the liver. Therefore, patients with severe liver function impairment should avoid using this drug. For patients with hepatic insufficiency, special caution should be used when using it, and the dosage should be adjusted according to the doctor's recommendations to avoid adverse reactions caused by drug accumulation.

5. Patients with severely impaired renal function: Although the kidneys have little impact on the metabolism of this drug, patients with severe renal insufficiency still need to be cautious when using this drug, especially adjustments based on doctor's advice and monitoring. Patients with renal impairment may be at increased risk of side effects during use.

6. Patients with compromised immune systems: Somituximab, as an immunomodulatory drug, has a certain impact on the immune system. Therefore, patients with weak immune function or in an immunosuppressed state should avoid using this drug unless under strict supervision by a doctor. Immune system suppression may cause medications to be less effective than expected and may even induce complications such as infection.

Reference materials:https://www.elahere.com/